A
Aleksandra Butrym
Researcher at Wrocław Medical University
Publications - 87
Citations - 1804
Aleksandra Butrym is an academic researcher from Wrocław Medical University. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 15, co-authored 76 publications receiving 1318 citations. Previous affiliations of Aleksandra Butrym include University of Wrocław.
Papers
More filters
Journal ArticleDOI
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Hervé Dombret,John F. Seymour,Aleksandra Butrym,Agnieszka Wierzbowska,Dominik Selleslag,Jun Ho Jang,Rajat Kumar,James Cavenagh,Andre C. Schuh,Anna Candoni,Christian Recher,Irwindeep Sandhu,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Giovanni Martinelli,Jose F Falantes,Richard Noppeney,Richard Stone,Mark D. Minden,Heidi McIntyre,S. Songer,Lela M. Lucy,C.L. Beach,Hartmut Döhner +23 more
TL;DR: Univariate analysis showed favorable trends for azacitidine compared with CCR across all subgroups defined by baseline demographic and disease features, and adverse events were consistent with the well-established safety profile of azacItidine.
Journal ArticleDOI
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Artur Jurczyszyn,Norbert Grzasko,Norbert Grzasko,Alessandro Gozzetti,Jacek Czepiel,Alfonso Cerase,Vania Hungria,Edvan de Queiroz Crusoe,Ana Luiza Miranda Silva Dias,Ravi Vij,Mark A. Fiala,Jo Caers,Leo Rasche,Ajay K. Nooka,Sagar Lonial,David H. Vesole,Sandhya Philip,Shane A Gangatharan,Agnieszka Druzd-Sitek,Jan Walewski,Alessandro Corso,Federica Cocito,Marie Christine M. Vekemans,Erden Atilla,Meral Beksac,Xavier Leleu,Julio Dávila,Ashraf Z. Badros,Ekta Aneja,Niels Abildgaard,Efstathios Kastritis,Dorotea Fantl,Natalia Schutz,Tomas Pika,Aleksandra Butrym,Magdalena Olszewska-Szopa,Lidia Usnarska-Zubkiewicz,Saad Z. Usmani,Hareth Nahi,Chor S. Chim,Chaim Shustik,Krzysztof Madry,Suzanne Lentzsch,Alina Swiderska,Grzegorz Helbig,Renata Guzicka-Kazimierczak,Nikoletta Lendvai,Anders Waage,Kristian Thidemann Andersen,Hirokazu Murakami,Sonja Zweegman,Jorge J. Castillo +51 more
TL;DR: Although prognosis is generally poor, the survival of previously untreated patients and patients with favorable cytogenetic profile might be prolonged due to systemic treatment and/or radiotherapy.
Journal ArticleDOI
Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients.
Aleksandra Butrym,Justyna Rybka,Dagmara Baczyńska,Andrzej Tukiendorf,Kazimierz Kuliczkowski,Grzegorz Mazur +5 more
TL;DR: Low miR-204 expression in AML patients was showed and it was found to be an independent prognostic factor in this patient population, which was associated with shorter patients’ survival.
Journal ArticleDOI
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
John F. Seymour,John F. Seymour,Hartmut Döhner,Aleksandra Butrym,Agnieszka Wierzbowska,Dominik Selleslag,Jun Ho Jang,Rajat Kumar,James Cavenagh,Andre C. Schuh,Anna Candoni,Christian Recher,Irwindeep Sandhu,Teresa Bernal del Castillo,Haifa Kathrin Al-Ali,Jose F Falantes,Richard Stone,Mark D. Minden,Jerry Weaver,S. Songer,C.L. Beach,Hervé Dombret +21 more
TL;DR: Azacitidine may be the preferred treatment for patients with AML-MRC who are not candidates for intensive chemotherapy, particularly patients ages 65–74 years and those with intermediate-risk cytogenetics.
Journal ArticleDOI
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality.
Radosław Sierpiński,Krystian Josiak,Tomasz Suchocki,Katarzyna Wojtas-Polc,Grzegorz Mazur,Aleksandra Butrym,Piotr Rozentryt,Peter van der Meer,Josep Comín-Colet,Stephan von Haehling,Wojciech Kosmala,Monika Przewlocka-Kosmala,Waldemar Banasiak,Jolanta Nowak,Adriaan A. Voors,Stefan D. Anker,John G.F. Cleland,Piotr Ponikowski,Ewa A. Jankowska +18 more
TL;DR: The aims of this study were to identify the iron biomarker with the greatest accuracy for the diagnosis of ID in bone marrow in patients with ischaemic HF, and to establish the prevalence of ID using this biomarker and its prognostic value in HF patients.